Sonia Agrawal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sonia Agrawal has a total of 258 co-authors. Here are the top co-authors by number of shared publications:
- Alan Rosen
AstraZeneca 4 Discovery Sciences, BioPharma R&D Waltham, Massachusetts
18 shared publications - Anders Nelson
AstraZeneca 2 Bioscience, Oncology R&D Waltham, Massachusetts
18 shared publications - Azadeh Cheraghchi-Bashi
AstraZeneca 1 Bioscience, Oncology R&D Cambridge, United Kingdom
18 shared publications - Danielle Carroll
AstraZeneca 5 Translational Science, Oncology R&D Cambridge, United Kingdom
18 shared publications - Jerome T. Mettetal
AstraZeneca, Waltham, MA
18 shared publications - Lucy Ireland
AstraZeneca 1 Bioscience, Oncology R&D Cambridge, United Kingdom
18 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Table 3. Summary of data from selected breast and gastric cell panel in vitro screen with capivasertib, T-DXd and combination treatment.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Table 3. Summary of data from selected breast and gastric cell panel in vitro screen with capivasertib, T-DXd and combination treatment.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 1. Capivasertib plus T-DXd combination treatment activity in breast and gastric cell lines.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 1. Capivasertib plus T-DXd combination treatment activity in breast and gastric cell lines.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Table 1. Cell culture details
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Table 1. Cell culture details
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 3. In vitro capivasertib plus exatecan combination benefit in cell lines.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 3. In vitro capivasertib plus exatecan combination benefit in cell lines.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 6. Western blot total-protein markers in HER2-low (AN3CA, EFM19) and HER2-positive (KPL4) cell lines treated with capivasertib alone or in combination with T-DXd.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 6. Western blot total-protein markers in HER2-low (AN3CA, EFM19) and HER2-positive (KPL4) cell lines treated with capivasertib alone or in combination with T-DXd.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 13. Body weight of animals in anti-tumour studies.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 13. Body weight of animals in anti-tumour studies.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate composed of an anti-HER2 antibody and a cytotoxic topoisomerase I inhibitor, is approved for the treatment of HER2-positive (HER2+) and HER2-low breast cancer as well as HER2-high gastric and HER2-mutant lung cancer tumors. The AKT inhibitor capivasertib is approved for the treatment of HER2− estrogen receptor–positive breast cancer with alterations in PIK3CA, PTEN, and AKT-1. The potential for the combination of T-DXd with AKT inhibition to enhance antitumor activity was explored in HER2+ or HER2-low preclinical models. In vitro, combination activity was observed in both HER2-high– and HER2-low–expressing breast cancer as well as in gastric, endometrial, and ovarian models, irrespective of HER2 expression level or PI3K–AKT status pathway alterations. The T-DXd–capivasertib combination effect translated in vivo with increased antitumor benefit in HER2-expressing, PI3K–AKT pathway–altered tumor xenografts when compared with the combination of trastuzumab and capivasertib. In cell lines sensitive to the combination, combining T-DXd with capivasertib targeted complimentary pathways which resulted in disruption of the cell cycle and increased cell death. These results suggest that T-DXd combined with capivasertib has the potential to be active in HER2+ as well as HER2-low tumors independent of PI3K pathway alteration status.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate composed of an anti-HER2 antibody and a cytotoxic topoisomerase I inhibitor, is approved for the treatment of HER2-positive (HER2+) and HER2-low breast cancer as well as HER2-high gastric and HER2-mutant lung cancer tumors. The AKT inhibitor capivasertib is approved for the treatment of HER2− estrogen receptor–positive breast cancer with alterations in PIK3CA, PTEN, and AKT-1. The potential for the combination of T-DXd with AKT inhibition to enhance antitumor activity was explored in HER2+ or HER2-low preclinical models. In vitro, combination activity was observed in both HER2-high– and HER2-low–expressing breast cancer as well as in gastric, endometrial, and ovarian models, irrespective of HER2 expression level or PI3K–AKT status pathway alterations. The T-DXd–capivasertib combination effect translated in vivo with increased antitumor benefit in HER2-expressing, PI3K–AKT pathway–altered tumor xenografts when compared with the combination of trastuzumab and capivasertib. In cell lines sensitive to the combination, combining T-DXd with capivasertib targeted complimentary pathways which resulted in disruption of the cell cycle and increased cell death. These results suggest that T-DXd combined with capivasertib has the potential to be active in HER2+ as well as HER2-low tumors independent of PI3K pathway alteration status.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 7. Western blot analysis of NCI-N87 cells treated with capivasertib, T-DXd monotherapy or the combination.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 7. Western blot analysis of NCI-N87 cells treated with capivasertib, T-DXd monotherapy or the combination.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 4. Capivasertib plus exatecan combination activity in breast and gastric cell lines.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 4. Capivasertib plus exatecan combination activity in breast and gastric cell lines.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 17 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 17. In vivo efficacy of capivasertib plus T-DXd in AN3CA and SKOV3
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 17 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
Supplementary Figure 17. In vivo efficacy of capivasertib plus T-DXd in AN3CA and SKOV3